Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status approved; investigational
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 49706-2103; 59285-010; 66039-871; 31722-030; 43598-852; 45963-454; 45963-456; 67877-552; 69238-1703; 69452-161; 69539-200; 70700-271; 70771-1410; 70771-1471; 58032-2017; 0078-0468; 0078-0469; 31722-013; 43598-854; 69238-1488; 69452-159; 69539-023; 46708-410; 57664-768; 62332-324; 62756-568; 69539-021; 69539-073; 69539-199; 62332-412; 67877-550; 67877-553; 69097-391; 69097-560; 69539-022; 70771-1472; 65727-037; 0078-0655; 42806-371; 43598-851; 67877-554; 68462-495; 68462-496; 69097-392; 70710-1012; 62512-0078; 0078-0470; 0078-0654; 0078-0720; 31722-029; 43598-856; 46708-411; 46708-412; 69097-393; 69238-1486; 69539-303; 70710-1276; 72205-176; 14501-0049; 63278-1070; 65085-0063; 66022-0301; 0078-0656; 31722-031; 43598-855; 57664-769; 62332-325; 62756-569; 69539-075; 70710-1011; 72205-075; 72647-372; 74436-0323; 31722-012; 43598-853; 62332-326; 62332-411; 62756-570; 68462-494; 69097-570; 69238-1487; 69238-1702; 69238-1704; 70710-1013; 70771-1411; 70771-1473; 0591-3853; 72647-371; 0591-2961; 11722-040; 53104-7713; 59651-419; 0078-0727; 42806-372; 46708-324; 46708-325; 57664-770; 67877-549; 69539-074; 70700-270; 72205-076; 65015-738; 0078-0713; 31722-011; 42806-373; 45963-455; 46708-326; 62332-410; 67877-551; 69097-550; 69452-160; 70700-269; 70710-1275; 70710-1277; 70771-1409; 72647-373; 65372-1164
UNII V8G4MOF2V9
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.030854%Not Available
Cholangitis09.02.01.0020.001239%Not Available
Cholecystitis09.03.01.0010.001859%
Cholecystitis acute09.03.01.0030.003098%Not Available
Cholelithiasis09.03.01.0020.011772%Not Available
Cholestasis09.01.01.0010.007435%Not Available
Chromaturia20.02.01.0020.031597%
Chronic lymphocytic leukaemia16.01.06.001; 01.10.06.0010.001859%Not Available
Chronic myelomonocytic leukaemia16.01.04.004; 01.10.04.0040.001239%Not Available
Coagulopathy01.01.02.0010.002478%Not Available
Colitis07.08.01.0010.004956%
Colitis ischaemic24.04.08.012; 07.08.01.0040.001859%Not Available
Coma17.02.09.0010.011152%Not Available
Coma hepatic17.02.09.002; 09.01.03.0050.001239%Not Available
Condition aggravated08.01.03.0040.038784%Not Available
Constipation07.02.02.0010.058982%
Cough22.02.03.001--
Crying19.04.02.002; 17.02.05.013; 12.02.11.001; 08.01.03.005--Not Available
Deafness04.02.01.0010.024039%Not Available
Deafness neurosensory04.02.01.002; 17.04.07.0010.003098%Not Available
Death08.04.01.0010.380285%
Decreased activity19.11.01.002; 08.01.01.0060.003346%Not Available
Decreased immune responsiveness10.02.01.0410.005576%Not Available
Decubitus ulcer23.03.11.0060.001859%Not Available
Dehydration14.05.05.0010.028995%
Delayed puberty21.03.02.014; 05.05.03.0030.003346%
Dental caries07.09.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.0030.001239%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 18 Pages